<DOC>
	<DOC>NCT02092597</DOC>
	<brief_summary>The purpose of this study is to assess the effects of incretin-based antidiabetic therapies (DPP-4 inhibitors and GLP-1 agonists) on cardiovascular, gastrointestinal and renal system and to detail the mechanisms underlying their action in these systems.</brief_summary>
	<brief_title>Safety Evaluation of Adverse Reactions in Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Type 2 diabetes mellitus Metformin monotherapy stable dose during last 3 months HbA1C 4875 mmol/mol (IFCC) BMI 2540 kg/m2 Age 3570 years (women postmenopausal) Use of ACE inhibitors or ATII receptor blockers for at least 3 months before enrollment eGFR&lt;30 ml/min/1.73m2 (MDRD) Treatment with incretin mimetics during 3 months before enrollment Chronic insulin therapy Chronic use of loop diuretics, glucocorticoids, NSAID, immune suppressants, antimicrobial agents, chemotherapeutics, bile acid sequestrants (colestyramin, colesevelam) History of pancreatic disease or impaired pancreatic function (defined as the need to use pancreatic enzymes) Active liver disease or a 3fold elevation of liver transaminases (ALT, AST) Active malignancy History of severe cardiovascular disease including acute coronary syndrome, stroke or transient ischemic neurologic disorder during previous 6 months, atrial fibrillation or other arrhythmia requiring chronic antiarrhythmic medication, chronic heart failure (New York Heart Association grade III/IV) History of alcohol abuse, defined as &gt;4 units of alcohol/day (32 g or 40 ml of 100% alcohol) History of allergy for GLP1 receptor agonists or DPP4 inhibitors Any disease that could interfere with study procedures (e.g. decreased mobility, mental incapacity) Inability to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>